Established in the year 1979, Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Company develops and manufactures affordable and innovative medicines for healthier lives.
The company has developed 300 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others.
For the next phase of growth, company is building a strong portfolio in lifestyle and chronic segment especially women healthcare and dermatology to complement its strong presence in acute segment.
Workforce & Production
Company has a strong and dedicated field force of over 600 personnel to cater to more than 30,000 doctors, chemists across the country. Company has a wide national distribution network through 21+ C&F agents and over 50000 retailers. Medicines of Lincoln Pharma reaches the target market segments through its sales and marketing divisions.
Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP and ISO-9001: 2015. The company is engaged in manufacturing of pharma formulations i.e Tablets, Capsules, Injectables, Dry Syrups, Ointments etc. Recently the company has also received approval from Australia’s medicines and medical devices regulator – Therapeutic Goods Administration (TGA) for its Khatraj facility.
To expand the production facility and launch Cephalosporin products, Lincoln Pharma has set up an ultramodern manufacturing plant in Mehsana, Gujarat. Mehsana facility is been designed as per the PIC’s and European Region and has received WHO-GMP certifications. The company is engaged in the manufacturing of Tablet capsules, Dry Syrup and Dry Powder Injection products for this plant. The company acquired the facility in the year 2021 and subsequently completed capacity expansion at the facility. Cephalosporin is a bactericidal, broad-spectrum, and β-lactam antibiotic originally derived from fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis and others.
Vision & Environment
Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create “Healthcare for All”.
For the FY ended March 2022, company posted net sales of Rs. 472.08 crore and earned net profit of Rs. 69.48 crore. Over the next 2-3 years company has plan to cross sales of over Rs. 600 crores. Company has the vision to enter the league of ‘Top 50 Pharma Companies’ of India in the near future.
Going green, company has also set up a new Solar Plant of 1 MW at factory’s rooftop in addition to two windmills. This has resulted in significant savings in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization.